Search Results - "Magera, James S"

Artificial urinary sphincter infection: causative organisms in a contemporary series by Magera, Jr, James S, Elliott, Daniel S

“…Traditionally Staphylococcus epidermidis has been the primary organism responsible for genitourinary prosthetic infection. However, the increasing prevalence…”
Get more information

Tandem transcorporal artificial urinary sphincter cuff salvage technique: surgical description and results by Magera, Jr, James S, Elliott, Daniel S

“…Complications associated with placement of artificial urinary sphincter may make reoperation necessary. We present a surgical description and outcome data for…”
Get more information

Outcome analysis of urethral wall stent insertion with artificial urinary sphincter placement for severe recurrent bladder neck contracture following radical prostatectomy by Magera, Jr, James S, Inman, Brant A, Elliott, Daniel S

“…We present outcome and quality of life analyses for the treatment of post-radical prostatectomy bladder neck contracture with urethral wall stent insertion and…”
Get more information

Silodosin for Benign Prostatic Hyperplasia by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Hemerson, Phyllis, Magera, James S, Jr

“…To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved alpha(1A)-adrenergic receptor (AR) antagonist for…”
Get full text

Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement? by Magera, Jr, James S, Inman, Brant A, Elliott, Daniel S

“…We determined if the incidence of a perioperative surgical site-positive culture was reduced by a 5-day topical antimicrobial scrub before implantation of an…”
Get more information

Association of Abnormal Preoperative Laboratory Values with Survival After Radical Nephrectomy for Clinically Confined Clear Cell Renal Cell Carcinoma by Magera, James S, Leibovich, Bradley C, Lohse, Christine M, Sengupta, Shomik, Cheville, John C, Kwon, Eugene D, Blute, Michael L

“…Objectives To determine whether preoperative laboratory values are independently associated with death from clinically confined clear cell renal cell carcinoma…”
Get full text

Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant by Magera, Jr, James S, Frank, Igor, Lohse, Christine M, Leibovich, Bradley C, Cheville, John C, Blute, Michael L

“…We evaluated the safety and oncological efficacy of repeat nephron sparing surgery in a renal remnant. We identified 18 patients who underwent 22 repeat…”
Get more information

Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy by Magera, Jr, James S, Inman, Brant A, Slezak, Jeffrey M, Bagniewski, Stephanie M, Sebo, Thomas J, Myers, Robert P

“…We compared the positive surgical margin rate of 2.5x and 4.3x optical loupe magnification with associated technical improvement during open radical retropubic…”
Get more information

Robot-assisted laparoscopic transvesical diverticulectomy and simple prostatectomy by Magera, James S., Adam Childs, M., Frank, Igor

“…Acquired bladder diverticula are often associated with bladder outlet obstruction (BOO). The increased voiding pressures required to overcome the BOO attenuate…”
Get full text

Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion by THOMPSON, Robert Houston, BLUTE, Michael L, KRAMBECK, Amy E, LOHSE, Christine M, MAGERA, James S, LEIBOVICH, Bradley C, KWON, Eugene D, FRANK, Igor, CHEVILLE, John C

“…Prior studies suggest that the renal sinus permits early tumor spread in otherwise localized renal cell carcinoma (RCC) tumors. We hypothesized that renal…”
Get full text

New Drug Approvals: Silodosin for Benign Prostatic Hyperplasia by Cantrell, Matthew A, Bream-Rouwenhorst, Heather R, Hemerson, Phyllis, Magera, James S

“…Objective: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved α1A-adrenergic receptor (AR) antagonist…”
Get full text